Vivus 'fesses up to another setback for Qsymia sales

Vivus ($VVUS) is in a jam with its brand-new obesity drug. Qsymia wasn't expected to storm out of the gate, but it wasn't expected to take a leisurely stroll, either. And now the company has another problem: After a slow-but-steady build in new prescriptions, Vivus has discovered that a sizable group of patients aren't filling their scrips because of high out-of-pocket costs. That's one reason why Vivus' third quarter results fell short, with a larger-than-expected loss of $40.4 million. And that's one reason why analysts are tempering their expectations for Qsymia sales. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.